Physician profile
Amina Chatha
NPI 1851559686
$4,033.13
in general payments reported to CMS, 2019-2025
23 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $246 · 2021: $270 · 2022: $478 · 2023: $111 · 2024: $671 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.40 | 2019-2025 | |
| Amgen INC. | $614.44 | 2019-2025 | Evenity, Enbrel, Otezla |
| Ucb, INC. | $442.66 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $375.81 | 2020-2025 | Tremfya |
| Pfizer INC. | $343.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $281.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $240.31 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $119.65 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $113.92 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.86 | 2019-2024 | |
| Sobi, INC | $92.42 | 2019-2023 | |
| Genentech USA, INC. | $67.12 | 2019-2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $63.18 | 2021-2025 | Acthar |
| Radius Health, INC. | $60.12 | 2023-2025 | Tymlos |
| Antares Pharma, INC. | $53.81 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.93 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $31.95 | 2024 | Strensiq |
| Lilly USA, LLC | $23.93 | 2019 | |
| Fresenius Kabi USA, LLC | $21.46 | 2023 | |
| Hikma Pharmaceuticals USA | $20.92 | 2019 | |
| Medexus Pharma, INC. | $20.26 | 2019 | |
| Pacira Therapeutics, INC. | $18.19 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Chatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.